Q1 2026 · 13F-HR
Foresite Capital Management V, LLCholdings as filed
Filed 2026-05-15 · accession 0001104659-26-062464
$271.0M
Reported value
9
Positions
2026-03-31
Period end
The Brief · Foresite Capital Management V, LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management V, LLC closed its position in Natera, Inc. NTRA, reducing its exposure by $15.4M. The fund established new positions in Eikon Therapeutics, Inc. EIKN for $13.9M, Pharvaris N.V. for $5.4M, and Nurix Therapeutics, Inc. NRIX for $4.1M. Additionally, the fund increased its stake in Hims & Hers Health, Inc. HIMS by 170.2%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 022307102 | ALMS | ALUMIS INC. | $129.9M | 47.9% | 5,896,995 | Common | SOLE |
| 156944100 | CGON | CG Oncology, Inc. | $68.0M | 25.1% | 1,004,050 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $23.9M | 8.83% | 374,069 | Common | SOLE |
| 433000106 | HIMS | Hims & Hers Health, Inc. | $15.3M | 5.65% | 738,151 | Common | SOLE |
| 282564103 | EIKN | Eikon Therapeutics, Inc. | $14.0M | 5.15% | 1,318,983 | Common | SOLE |
| 55083R203 | LYEL | Lyell Immunopharma, Inc. | $9.6M | 3.53% | 477,078 | Common | SOLE |
| N69605108 | PHVS | Pharvaris N.V. | $5.5M | 2.02% | 194,125 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $4.1M | 1.52% | 265,000 | Common | SOLE |
| 578784100 | MAZE | Maze Therapeutics, Inc. | $773,264 | 0.29% | 25,905 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.